Xenetic Biosciences (XBIO) Change in Account Payables (2011 - 2013)
Xenetic Biosciences' (XBIO) quarterly Change in Account Payables came in at -$121055.0 in Q4 2013, down 410.93% YoY from $38933.0 in Q4 2012, and down 142.89% on a QoQ basis from $282235.0 in Q3 2013.
Xenetic Biosciences (XBIO) Change in Account Payables (2011 - 2013) Analysis & Trends
Xenetic Biosciences (XBIO) has 3 years of Change in Account Payables data on file, last reported at -$121055.0 in Q4 2013.
- Quarterly Change in Account Payables fell 410.93% year-over-year to -$121055.0 in Q4 2013, while the trailing twelve-month figure through Nov 2013 was $239026.0 (up 30.41% YoY) and the FY2013 annual result came in at $239026.0, up 30.41% from the prior year.
- Change in Account Payables retreated to -$121055.0 in Q4 2013, from $282235.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $282235.0 in Q3 2013 to a low of -$121055.0 in Q4 2013.
- A 3-year average of $48828.6 and a median of $38933.0 in 2012 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 367.08% in 2013, down 410.93% in 2013.
- Tracing XBIO's Change in Account Payables over 3 years: stood at $17138.0 in 2011, then surged by 127.17% to $38933.0 in 2012, then plunged by 410.93% to -$121055.0 in 2013.
- The last three Change in Account Payables figures came in at -$121055.0 (Q4 2013), $282235.0 (Q3 2013), and $17147.0 (Q2 2013), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -121,055.00 |
| Nov 30, 2013 | -121,055.00 |
| Aug 31, 2013 | 282,235.00 |
| Aug 31, 2013 | 282,235.00 |
| May 31, 2013 | 17,147.00 |
| May 31, 2013 | 17,147.00 |
| Feb 28, 2013 | 60,699.00 |
| Feb 28, 2013 | 60,699.00 |
| Nov 30, 2012 | 38,933.00 |
| Nov 30, 2012 | 38,933.00 |
| Aug 31, 2012 | 60,426.00 |
| Aug 31, 2012 | 60,426.00 |
| May 31, 2012 | 53,443.00 |
| May 31, 2012 | 53,443.00 |
| Feb 29, 2012 | 30,491.00 |
| Feb 29, 2012 | 30,491.00 |
| Nov 30, 2011 | 17,138.00 |
| Nov 30, 2011 | 17,138.00 |